These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15663888)

  • 21. Neuroprotective possibilities for Huntington's disease.
    Emerich DF
    Expert Opin Biol Ther; 2001 May; 1(3):467-79. PubMed ID: 11727519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models.
    Ehrnhoefer DE; Duennwald M; Markovic P; Wacker JL; Engemann S; Roark M; Legleiter J; Marsh JL; Thompson LM; Lindquist S; Muchowski PJ; Wanker EE
    Hum Mol Genet; 2006 Sep; 15(18):2743-51. PubMed ID: 16893904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental surgical therapies for Huntington's disease.
    Demeestere J; Vandenberghe W
    CNS Neurosci Ther; 2011 Dec; 17(6):705-13. PubMed ID: 21199443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of immunity in Huntington's disease.
    Soulet D; Cicchetti F
    Mol Psychiatry; 2011 Sep; 16(9):889-902. PubMed ID: 21519341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic options for Huntington's disease.
    Grimbergen YA; Roos RA
    Curr Opin Investig Drugs; 2003 Jan; 4(1):51-4. PubMed ID: 12625029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Huntington's disease: clinical characteristics, pathogenesis and therapies.
    Nakamura K; Aminoff MJ
    Drugs Today (Barc); 2007 Feb; 43(2):97-116. PubMed ID: 17353947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.
    Guidetti P; Reddy PH; Tagle DA; Schwarcz R
    Neurosci Lett; 2000 Apr; 283(3):233-5. PubMed ID: 10754231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Huntington disease. A review].
    Bonilla E
    Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug targeting of dysregulated transcription in Huntington's disease.
    Kazantsev AG; Hersch SM
    Prog Neurobiol; 2007 Nov; 83(4):249-59. PubMed ID: 17379386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.
    Leegwater-Kim J; Cha JH
    NeuroRx; 2004 Jan; 1(1):128-38. PubMed ID: 15717013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteomic Analysis of Huntington's Disease.
    Kumar S; Singh P; Sharma S; Ali J; Baboota S; Pottoo FH
    Curr Protein Pept Sci; 2020; 21(12):1218-1222. PubMed ID: 33023443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits.
    Aharony I; Ehrnhoefer DE; Shruster A; Qiu X; Franciosi S; Hayden MR; Offen D
    Hum Mol Genet; 2015 May; 24(9):2604-14. PubMed ID: 25616965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
    Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
    Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD.
    Andrich J; Saft C; Arz A; Schneider B; Agelink MW; Kraus PH; Kuhn W; Müller T
    Mov Disord; 2004 Feb; 19(2):226-8. PubMed ID: 14978683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small molecule drug discovery for Huntington's Disease.
    Fecke W; Gianfriddo M; Gaviraghi G; Terstappen GC; Heitz F
    Drug Discov Today; 2009 May; 14(9-10):453-64. PubMed ID: 19429504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mechanisms of neuronal death in Huntington's disease. First part: general considerations and histopathological features].
    Bantubungi K; Blum D
    Rev Med Brux; 2007; 28(5):413-21. PubMed ID: 18069515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypothalamic-endocrine aspects in Huntington's disease.
    Petersén A; Björkqvist M
    Eur J Neurosci; 2006 Aug; 24(4):961-7. PubMed ID: 16925587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin.
    Ruan Q; Quintanilla RA; Johnson GV
    J Neurochem; 2007 Jul; 102(1):25-36. PubMed ID: 17403029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [From gene to disease; HD gene and Huntington disease].
    Maat-Kievit JA; Losekoot M; Roos RA
    Ned Tijdschr Geneeskd; 2001 Nov; 145(44):2120-3. PubMed ID: 11723754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stem cell therapy and cellular engineering for treatment of neuronal dysfunction in Huntington's disease.
    Choi KA; Hwang I; Park HS; Oh SI; Kang S; Hong S
    Biotechnol J; 2014 Jul; 9(7):882-94. PubMed ID: 24827816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.